Bonesupport Holding AB

BONEX

SE0009858152

Pharmaceuticals

Market Closed - Nasdaq Stockholm Other stock markets 12:00:00 2026-05-20 pm EDT			5-day change	1st Jan Change
258.60 ^SEK	+3.94%		+8.47%	+37.55%

May. 19	Qube closes short positions in Invisio, Camurus and Bonesupport	FW
May. 13	Bonesupport Chairman acquires shares worth over SEK 0.3 million	FW

BONESUPPORT’s CERAMENT®G used in first U.S. patient cases

Published on 10/24/2022 at 08:00 am EDT - Modified on 10/24/2022 at 08:01 am EDT

Acquiremedia

BONESUPPORT HOLDING AB

+3.94%

BONESUPPORT, an emerging leader in orthobiologics for the management of bone injuries, today announces that the company’s antibiotic-eluting bone graft CERAMENT G (Gentamicin) has been used surgically for the first time in patients in the US. The patients treated had bone infection (osteomyelitis) caused by fractures induced by trauma.

“CERAMENT G is truly changing the way we can treat osteomyelitis by more directly and effectively addressing the site of the infection in a single stage, patient friendly surgical approach. CERAMENT G has been widely used with great success in other parts of the world and I’m pleased to integrate it in my clinical practice,” said Janet D. Conway, MD, FAAOS, board-certified orthopedic surgeon and Head of Bone and Joint Infection at Sinai Hospital of Baltimore, who carried out the first surgeries using CERAMENT G in the US.

BONESUPPORT received authorization for CERAMENT G in the management of osteomyelitis from the US Food and Drug Administration (FDA) earlier this year. The extensive clinical documentation on which the market approval is based, shows that CERAMENT G reduces the risk of recurrent bone infection to 4.3–5.5 percent versus 13.3 percent for the current US standard of care, PMMA-beads. CERAMENT G is the first and only FDA authorized combination antibiotic-eluting bone graft.

About BONESUPPORT™

BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs. BONESUPPORT’s bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver. The company is based in Lund, Sweden, and the net sales amounted to SEK 213 million in 2021. Please visit www.bonesupport.com for more information.
BONESUPPORT and CERAMENT are registered trademarks of BONESUPPORT AB.

Latest news about Bonesupport Holding AB

May. 19	Qube closes short positions in Invisio, Camurus and Bonesupport	FW
May. 13	Bonesupport Chairman acquires shares worth over SEK 0.3 million	FW
May. 13	Bonesupport board member Christine Rankin increases shareholding	FW
May. 12	Bonesupport Holding AB Approves the Election of Emil Billbäck as Director	CI
May. 12	Bonesupport board member Jens Viebke increases shareholding	FW
May. 06	Kavaljer Quality Focus gains 2.1 percent in April - sees attractive opportunities in medtech	FW
May. 05	Aggregate short positions on the Stockholm Stock Exchange as of May 5	FW
Apr. 27	Adrigo Small & Midcap L/S down 8.0 percent in March - geopolitical unrest weighed on the market	FW
Apr. 23	DNB Carnegie trims Bonesupport price target to SEK 390 (400), reiterates Buy	FW
Apr. 23	SEB raises Bonesupport price target to SEK 285 (270), reiterates Buy	FW
Apr. 22	Mixed performance on earnings-heavy Stockholm bourse, OMXS30 index slips 0.2 percent	FW
Apr. 22	Mixed trading on earnings-heavy Stockholm bourse, OMXS30 index edges up 0.2 percent	FW
Apr. 22	Bonesupport Holding AB, Q1 2026 Earnings Call, Apr 22, 2026
Apr. 22	Bonesupport Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
Apr. 22	Stockholm stocks edge higher at the open as major banks rally on earnings	FW

Chart Bonesupport Holding AB

Duration

Period

BONEX: Dynamic Chart

Company Profile

Bonesupport Holding AB is a Sweden-based orthobiologics company. It develops and commercialize injectable bioceramic bone graft substitutes which remodel to host bone and have the capability to elute drugs directly into the bone void. The marketed synthetic bone graft substitutes are CERAMENT BVF, CERAMENT G and CERAMENT V, which are based on the CERAMENT technology platform. The products are commercially available in Europe and the United States, as well as in India, Malaysia, Oman and Singapore. The products are developed to treat patients with fractures and bone voids caused by trauma and related surgery, as well as caused by infection or diseases, such as chronic osteomyelitis, revision arthroplasty and infected diabetic foot.

Employees

160

Sector

Pharmaceuticals

Calendar

Earnings release - Q2 2026

More about the company